Safety study of Lu AH69593 for healthy adults or narcolepsy
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether a new medication called Lu AH69593 is safe and well-tolerated in healthy adults and people with narcolepsy type 1. Researchers want to understand how the drug affects the body and whether it could help treat excessive daytime sleepiness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Resting heart rate between 45 and 100 beats per minute
- Body mass index (BMI) between 18.5 and 30 (or up to 35 if you have narcolepsy)
- Age 18–55 years old (up to 64 if you have narcolepsy)
- Normal sleep schedule: usually wake between 6–9 a.m. and sleep between 9 p.m.–midnight
- Not pregnant, breastfeeding, or planning to become pregnant without using contraception
- No recent clinical trial participation (at least 30 days since last trial)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called E2086 to see if it can help reduce daytime sleepiness and sudden muscle weakness in adults with narcolepsy. It involves two groups: people with cataplexy (type 1) and those without (type 2).
This study tests a new medicine, HBS-301, for people with narcolepsy type 1 or type 2 who still have excessive daytime sleepiness. If you take other medications for sleepiness or mood, they must be stable for at least 3 months, and you cannot take some as-needed sleepiness medicines.
This study tests whether a new medication called samelisant can reduce extreme daytime sleepiness and sudden muscle weakness (cataplexy) in people with narcolepsy. If it works, it could offer a new treatment option for managing this sleep disorder.
This study tests a new medication, ALKS 2680, to see if it helps reduce daytime sleepiness and other symptoms in adults with narcolepsy type 1. It may offer a new treatment option for people with this condition.
This study tests whether a new medication called ALKS 2680 can help people with narcolepsy type 1 stay more awake and alert during the day. Narcolepsy type 1 is a neurological condition where people fall asleep unexpectedly and may experience sudden muscle weakness.
This study tests an investigational drug called ALKS 2680 for people with narcolepsy type 2, a condition that causes excessive daytime sleepiness without sudden muscle weakness. The goal is to see if the drug is safe and helps reduce daytime sleepiness.
Hear when a new Narcolepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.